摘要
背景:β地中海贫血的表型严重程度受β-珠蛋白突变、α-地中海贫血的共遗传和与胎儿血红蛋白产生相关基因的多态性三种遗传修饰因子的高度调控。本研究旨在探讨HBF相关基因主要存在于HBB簇、BCL11A(B细胞CLL/淋巴瘤11A)和HBS1L-MYB(HBS 1样翻译型GTPase-MYB原癌基因、转录因子)对临床严重程度的影响。方法:对149例患者进行调查。采用多重PCR、Sanger测序和多重连接依赖探针扩增技术对HBA和HBB突变进行分析。此外,采用质谱和PCR-限制性片段长度多态性(PCRRFLP)对35种HBF多态性进行了基因分型。用SPSSVersion 22进行基因型-表型关联分析。结果:在研究人群中发现了21个HBB突变.HBB突变患者由于其他次级修饰物的存在,其表型严重程度不同。α-地中海贫血的共遗传(n=12)减轻了β-地中海贫血的疾病严重程度.3种多态性(HBS1LMYB,rs4895441[P=0.008,OR=0.38(0.18,0.78)],rS 9376092[P=0.030,OR=0.36(0.14,0.90)];嗅觉受体[OR51B2]rs6578605[P=0.018,OR=0.52(0.31,0.89)]与表型严重程度有关。对HBF单核苷酸多态性与HBF水平关系的二次分析表明,HBS1L-MYB中有三个表面意义显著的SNPs:rs 6934903、rs 9376095和rs 9494149。结论:本研究揭示了3种HBF多态性在改善β-地中海贫血患者病情严重程度中的重要作用,可作为临床管理的预测指标。
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
Current Molecular Medicine
Title:Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients
Volume: 18 Issue: 5
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
摘要: Background: The phenotypic severity of β-thalassemia is highly modulated by three genetic modifiers: β-globin (HBB) mutations, co-inheritance of α-thalassemia and polymorphisms in the genes associated with fetal haemoglobin (HbF) production. This study was aimed to evaluate the effect of HbF related polymorphisms mainly in the HBB cluster, BCL11A (B-cell CLL/lymphoma 11A) and HBS1L-MYB (HBS1-like translational GTPase-MYB protooncogene, transcription factor) with regards to clinical severity.
Methods: A total of 149 patients were included in the study. HBA and HBB mutations were characterised using multiplex PCR, Sanger sequencing and multiplex ligationdependent probe amplification. In addition, 35 HbF polymorphisms were genotyped using mass spectrometry and PCR-restriction fragment length polymorphism (PCRRFLP). The genotype-phenotype association was analysed using SPSS version 22.
Results: Twenty-one HBB mutations were identified in the study population. Patients with HBB mutations had heterogeneous phenotypic severity due to the presence of other secondary modifiers. Co-inheritance of α-thalassemia (n = 12) alleviated disease severity of β-thalassemia. In addition, three polymorphisms (HBS1LMYB, rs4895441 [P = 0.008, odds ratio (OR) = 0.38 (0.18, 0.78)], rs9376092 [P = 0.030, OR = 0.36 (0.14, 0.90)]; and olfactory receptor [OR51B2] rs6578605 [P = 0.018, OR = 0.52 (0.31, 0.89)]) were associated with phenotypic severity. Secondary analysis of the association between single-nucleotide polymorphisms with HbF levels revealed three nominally significant SNPs: rs6934903, rs9376095 and rs9494149 in HBS1L-MYB.
Conclusion: This study revealed 3 types of HbF polymorphisms that play an important role in ameliorating disease severity of β-thalassemia patients which may be useful as a predictive marker in clinical management.
Export Options
About this article
Cite this article as:
Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004121604
DOI https://dx.doi.org/10.2174/1566524018666181004121604 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Effect of Selenium Enrichment of <i>Lenzites betulinus</i> and <i>Trametes hirsuta</i> Mycelia on Antioxidant, Antifungal and Cytostatics Potential
Current Pharmaceutical Biotechnology Synthesis and <i>In Vitro</i> Cytotoxic Evaluation of Novel Murrayafoline A Derived β-Amino Alcohols
Letters in Organic Chemistry Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry Viral Proteases as Targets for Drug Design
Current Pharmaceutical Design Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology NBS1 Heterozygosity and Cancer Risk
Current Genomics Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells
Current Molecular Medicine Synthesis and Biological Activity of 28-Amide Derivatives of 23-Hydroxy Betulinic Acid as Antitumor Agent Candidates
Medicinal Chemistry Emerging Immunotargets in Bladder Cancer
Current Drug Targets Small Molecule Inhibition of the Bcl-XL-BH3 Protein-Protein Interaction: Proof-of-Concept of an In Vivo Chemopotentiator ABT-737
Current Topics in Medicinal Chemistry Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews